Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04798014 · ClinicalTrials.gov registry record
HERO-2: Home-Reported Outcomes With CFTR Modulator Therapy
A clinical trial of Cystic Fibrosis, sponsored by Indiana University.
- Completed
- Registry status
- 860
- Enrollment target
- 1
- Study location
NCT04798014 is a study of Cystic Fibrosis that has completed, run by Indiana University. The registered enrollment target is 860 participants, above the 174-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (394% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04798014, a study of Cystic Fibrosis, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- 860 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational cohort study, using data from Folia Health and the Cystic Fibrosis Foundation Patient Registry (CFFPR). Individuals taking elexacaftor/tezacaftor/ivacaftor (ETI) may be enrolled through the Folia application. During the 12-month study period, participants will be asked to track their routine treatment and medication usage, daily symptoms, and monthly review with validated patient-reported outcome (PRO) questionnaires. Participants will also be asked to self-report instances of changes to their treatment plan, and pulmonary exacerbations. There are no study-associated site visits.
Conditions Studied
Study Locations (1)
Indiana
- Indiana University School of Medicine - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 860 participants |
| Start Date | 2021-05-26 |
| Est. Completion | 2023-08-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04798014
The ClinicalTrials.gov registry entry for NCT04798014 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 860 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 174-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (394% higher). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT04798014 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT04798014 about?
NCT04798014 is a clinical study titled "HERO-2: Home-Reported Outcomes With CFTR Modulator Therapy". This is an observational cohort study, using data from Folia Health and the Cystic Fibrosis Foundation Patient Registry (CFFPR). Individuals taking elexacaftor/tezacaftor/ivacaftor (ETI) may be enrolled through the Folia application. During the 12-month study period, participants will be asked to tr...
What is the current status of trial NCT04798014?
This trial is currently completed. The enrollment target is 860 participants. The study started on 2021-05-26. Estimated completion is 2023-08-15.
What conditions does trial NCT04798014 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
Who is sponsoring clinical trial NCT04798014?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04798014 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise in Child Health
RECRUITING · NA
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
RECRUITING
-
Assessing Tenapanor as a Treatment of CF-related Constipation.
RECRUITING · Phase 3
-
Genetics of Insulin and Incretins in Cystic Fibrosis
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.